Cargando…
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial
BACKGROUND: Chemotherapy-induced anemia (CIA) is responsive to treatment with erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa. Administration of ESAs on a synchronous schedule with chemotherapy administration could benefit patients by reducing clinic visits and potentially enhancin...
Autores principales: | Schwartzberg, Lee, Burkes, Ronald, Mirtsching, Barry, Rearden, Timothy, Silberstein, Peter, Yee, Lorrin, Inamoto, Amy, Lillie, Tom |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988026/ https://www.ncbi.nlm.nih.gov/pubmed/20973982 http://dx.doi.org/10.1186/1471-2407-10-581 |
Ejemplares similares
-
Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006) -
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020) -
Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011) -
Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014) -
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
por: Glaspy, J A, et al.
Publicado: (2002)